$5.37
+0.26(5.09%)
Mkt Cap $46M
$3.94
$17.70
52-Week Range
At a Glance
AI-generatedAtossa Therapeutics, Inc.
8-K
Atossa Therapeutics issued a press release on March 25, 2026, announcing fourth quarter and full year 2025 financial results, with total operating expenses of $37.1 million for the year ended December 31, 2025, up $9.5 million from $27.6 million in 2024, primarily due to increased R&D on (Z)-endoxifen trials. The company highlighted FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in DMD and management team additions.$46M
Market Cap
—
Revenue
-$30M
Net Income
Employees15
Fundamentals
How The Business Makes Money
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001488039
ISINUS04962H7044
CUSIP04962H704
Phone206 588 0256
Address107 Spring Street, Seattle, WA, 98104, US
SEC EDGAR